GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Starpharma Holdings Ltd (OTCPK:SPHRY) » Definitions » Forward PE Ratio

Starpharma Holdings (Starpharma Holdings) Forward PE Ratio : 0.00 (As of Jun. 07, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Starpharma Holdings Forward PE Ratio?

Starpharma Holdings's Forward PE Ratio for today is 0.00.

Starpharma Holdings's PE Ratio without NRI for today is 0.00.

Starpharma Holdings's PE Ratio for today is 0.00.


Starpharma Holdings Forward PE Ratio Historical Data

The historical data trend for Starpharma Holdings's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Starpharma Holdings Forward PE Ratio Chart

Starpharma Holdings Annual Data
Trend 2016-07 2017-12 2018-12 2019-04 2022-04
Forward PE Ratio
21.10 104.17 28.09 15.13 303.03

Starpharma Holdings Semi-Annual Data
2016-03 2016-06 2017-03 2017-06 2017-09 2017-12 2018-03 2018-06 2018-09 2018-12 2019-03 2022-03
Forward PE Ratio 18.76 18.35 97.09 53.76 129.87 104.17 46.73 35.21 46.51 28.09 13.76 333.33

Competitive Comparison of Starpharma Holdings's Forward PE Ratio

For the Biotechnology subindustry, Starpharma Holdings's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Starpharma Holdings's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Starpharma Holdings's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Starpharma Holdings's Forward PE Ratio falls into.



Starpharma Holdings Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Starpharma Holdings  (OTCPK:SPHRY) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Starpharma Holdings Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Starpharma Holdings's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Starpharma Holdings (Starpharma Holdings) Business Description

Traded in Other Exchanges
Address
4-6 Southampton Crescent, Abbotsford, Melbourne, VIC, AUS, 3067
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating and VIRALEZE an antiviral nasal spray.